Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 10, 2016 10:12 PM ET

Healthcare Providers and Services

Company Overview of 21st Century Oncology, LLC

Company Overview

21st Century Oncology, LLC develops and operates radiation therapy centers. The company provides radiation therapy services, including treatment for deepseated, head/neck, breast, and skin and surface tumors for cancer patients. The company also provides courtesy transportation, wheelchair, and stretcher services. The company was founded in 1985 and is based in Fort Myers, Florida. The company operates oncology centers in Alabama, Arizona, California, Delaware, Florida, Kentucky, Massachusetts, Maryland, Michigan, New Jersey, New York, Nevada, North Carolina, Rhode Island, and West Virginia. 21st Century Oncology, LLC operates as a subsidiary of 21st Century Oncology, Inc.

2234 Colonial Boulevard

Fort Myers, FL 33907

United States

Founded in 1985

Phone:

239-936-3756

Fax:

239-931-7300

Key Executives for 21st Century Oncology, LLC

Co-Founder, Chief Executive Officer, President and Radiation Oncologist
Age: 62
Controller, Chief Accounting Officer, Vice President, and Assistant Treasurer
Age: 46
Chief Technology Officer and Director of Physics and Engineering
Age: 60
Executive Vice President and General Counsel
Age: 63
Chief Compliance Officer and Senior Vice President
Age: 63
Compensation as of Fiscal Year 2015.

21st Century Oncology, LLC Key Developments

21st Century Oncology, LLC Presents at JPMorgan 34th Annual Healthcare Conference, Jan-12-2016 01:30 PM

21st Century Oncology, LLC Presents at JPMorgan 34th Annual Healthcare Conference, Jan-12-2016 01:30 PM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Daniel E. Dosoretz, Co-Founder, Chief Executive Officer, President and Radiation Oncologist, LeAnne Stewart, CFO.

21st Century Oncology, LLC Agrees to Pay $19.75 Million to the Federal Government and $528,000 in Attorneys' Fees and Costs Related to the Qui Tam Action

On December 16, 2015, 21st Century Oncology, LLC entered into a settlement agreement, with, among others, the United States of America and Mariela Barnes. Pursuant to the settlement agreement, the company agreed to pay $19.75 million to the federal government and $528,000 in attorneys' fees and costs related to the qui tam action brought by Ms. Barnes with respect to the previously disclosed dispute related to the fluorescence in situ hybridization (FISH) diagnostic test. The company is required to pay both amounts on or prior to the tenth business day following the date of the settlement agreement. Subject to certain conditions, the federal government agreed to release 21st Century Oncology from any civil or administrative monetary claim the federal government has with respect to the conduct covered by the settlement agreement under the False Claims Act and certain other statutes and legal theories, and Ms. Barnes agreed to release 21st Century Oncology from any claims she has on behalf of the federal government under the False Claims Act. The settlement agreement avoids the uncertainty and expense of protracted litigation and does not constitute an admission of liability by 21st Century Oncology.

21st Century Oncology, Inc. Reports Unaudited Consolidated Earnings Results and Operating Results for the Fourth Quarter and Full Year Ended December 31, 2013

21st Century Oncology, Inc. reported unaudited consolidated earnings results and operating results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported total revenues of USD 203.390 million compared to USD 168.736 million a year ago. Loss before income taxes was USD 34.905 million compared to USD 31.931 million a year ago. Net loss was USD 9.624 million compared to USD 33.222 million a year ago. Net loss attributable to the company was USD 10.225 million compared to USD 33.070 million a year ago. Comprehensive loss attributable to the company was USD 16.186 million compared to USD 35.574 million a year ago. Pro-forma adjusted EBITDA was USD 27.236 million compared to USD 24.164 million a year ago. The increase in revenue was principally due to increased census, accretive joint ventures and acquisitions and international revenue growth, offset by lower reimbursement rates. For the quarter, the company reported number of new 2D cases of 848 compared to 1,254 a year ago. The number of new 3D cases was 2,779 compared to 2,312 a year ago. IMRT /IGRT cases was 560 compared to 346 a year ago. For the year, the company reported total revenues of USD 736.516 million compared to USD 693.951 million a year ago. Loss before income taxes was USD 93.980 million compared to USD 146.584 million a year ago. Net loss was USD 73.548 million compared to USD 151.129 million a year ago. Net loss attributable to the company was USD 75.514 million compared to USD 154.208 million a year ago. Comprehensive loss attributable to the company was USD 90.443 million compared to USD 161.740 million a year ago. Net cash used in operating activities was USD 10.624 million compared to net cash provided by operating activities of USD 16.130 million a year ago. Purchase of property and equipment was USD 40.744 million compared to USD 30.676 million a year ago. Pro-forma adjusted EBITDA was USD 118.591 million compared to USD 104.691 million a year ago. The increase in revenue was principally due to increased domestic census, accretive joint ventures and acquisitions and international revenue growth, offset by lower reimbursement rates. For the year, the company reported number of new 2D cases of 3,716 compared to 4,857 a year ago. The number of new 3D cases was 10,418 compared to 8,901 a year ago. IMRT /IGRT cases was 1,956 compared to 1,471 a year ago.

Similar Private Companies By Industry

Company Name Region
BriovaRx, LLC United States
Long Term Solutions, Inc. United States
The Eye Surgery Center of the Carolinas, L.P. United States
Stephen B. Meisel, M.D., A Medical Corporation United States
CareGroup, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact 21st Century Oncology, LLC, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.